← Back to all trials
Not Yet Recruiting
NCT07811011
Efficacy of Vildagliptin Versus Metformin in Patients With Polycystic Ovary Syndrome
Conditions: Poly Cystic Ovary Syndrome
Sex: Female
Ages: 18 Years – 40 Years
Healthy volunteers: No
Phase: PHASE2, PHASE3
Enrollment: 70
Sponsor: Tanta University
Summary
Polycystic ovary syndrome (PCOS) is a common endocrine and metabolic disorder characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphology, with insulin resistance playing a central role in its pathophysiology. Hyperinsulinemia can enhance ovarian androgen production and reduce hepatic sex hormone-binding globulin synthesis, thereby aggravating hyperandrogenism and reproductive abnormalities. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances endogenous incretin activity and may improve insulin sensitivity and glucose homeostasis. Emerging evidence suggests that DPP-4 inhibition may also influence body weight, androgen excess, inflammation, and reproductive function in women with PCOS.
Eligibility Criteria
Inclusion Criteria:
Women diagnosed with PCOS according to Rotterdam 2003 criteria National Institute of Health criteria.
Age: \>18 \
Source: ClinicalTrials.gov (NCT07811011). StuddyBuddy aggregates publicly available trial information.
